This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $693,134 to Case Western Reserve University to conduct research on the molecular mechanisms underlying interactions between the EPHA1 and EPHA2 receptor tyrosine kinases and their roles in cancer development and progression. The research aims to elucidate the structural basis of EPHA1 homo-dimerization and EPHA1-EPHA2 hetero-interactions, and delineate their impact on cell signaling, migration, and invasion both in vitro and in vivo, with a focus on liver cancer. The findings are expected to advance the understanding of these receptors in human cancers and identify potential new therapeutic targets. The award has a period of performance from Dec 5, 2024 to Nov 30, 2029.
Generated 2/25/25, 2:53 AM